KSI-101

Phase 3

00%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

4mo

KODPhase 3$2.3B

KSI-101 Phase 3 Est. Readout

KSI-101• Macular Edema Secondary to Inflammation150

Dec 31ConfirmedSTALE

00%

Competitive Landscape

1 competitor in Macular Edema Secondary to Inflammation

Drug Information

Target Indication

Macular Edema Secondary to Inflammation

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

KOD

Kodiak Sciences Inc

Related Pipeline

Macular Edema

Diabetic Retinopathy

Wet Age-related Macular Degeneration

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts